Myocardial Infarction — Clinical Documentation Guide (2026)

🔍 Definition

Myocardial infarction (MI) is defined as acute myocardial injury with clinical evidence of acute myocardial ischemia, consistent with the Fourth Universal Definition of Myocardial Infarction (2018) jointly issued by the European Society of Cardiology (ESC), American College of Cardiology (ACC), American Heart Association (AHA), and World Heart Federation (WHF). The hallmark is detection of a rise and/or fall of cardiac troponin (cTn) with at least one value above the 99th percentile upper reference limit (URL), in the context of ischemic symptoms, new ECG changes, imaging evidence of new loss of viable myocardium, or intracoronary imaging identifying thrombus.

MI is broadly categorized into five types under the 4th Universal Definition. Type 1 MI results from spontaneous atherosclerotic plaque rupture, erosion, or fissuring with intraluminal thrombus formation in one or more coronary arteries, leading to decreased myocardial blood flow. Type 2 MI occurs secondary to a mismatch between myocardial oxygen supply and demand without coronary plaque rupture — for example, in the setting of sepsis, severe anemia, hypotension, or sustained tachyarrhythmia. Types 3 (sudden cardiac death), 4a/4b/4c (PCI-related), and 5 (CABG-related) represent procedure-related or fatal infarctions that lack post-procedural biomarker data.

Electrocardiographically, MI is classified as ST-elevation MI (STEMI) when persistent ST-segment elevation is present, reflecting complete coronary occlusion requiring immediate reperfusion therapy, or non-ST-elevation MI (NSTEMI), where the artery is partially occluded. The FY2026 ICD-10-CM classification fully reflects this clinical framework, with specific codes for STEMI by anatomical wall, NSTEMI, Type 2 MI, and subsequent infarctions occurring within 28 days.

🗂️ Alternative Terminology

Multiple lay and clinical terms are used interchangeably for myocardial infarction, which can create documentation ambiguity for coders and CDI specialists.

🩺 Signs & Symptoms

Classic presentation includes crushing, pressure-like substernal chest pain radiating to the left arm, jaw, or shoulder, often accompanied by diaphoresis, nausea, and dyspnea. However, atypical presentations are common, particularly in women, elderly patients, and diabetics, who may present with epigastric pain, fatigue, or syncope without classic chest pain.

• Chest pain / pressure: Onset usually at rest or with exertion; typically >20 minutes duration; not relieved by nitroglycerin
• Radiation: Left arm, jaw, neck, back, or right arm
• Diaphoresis: Cold sweat, pallor
• Dyspnea: Particularly in anterior STEMI with LV dysfunction
• Nausea/vomiting: More common in inferior MI (RCA distribution)
• Syncope or presyncope: Due to hemodynamic compromise or arrhythmia
• Palpitations: Ventricular ectopy, VT, VF common with acute ischemia
• Silent MI: Asymptomatic, detected only on ECG or imaging (common in diabetics)
• ECG findings: ST elevation (STEMI), ST depression/T-wave inversion (NSTEMI), new LBBB, pathological Q-waves
• Biomarkers: Elevated cardiac troponin I or T above 99th percentile URL; CK-MB elevation

🧭 Differential Diagnosis

Chest pain with troponin elevation requires systematic exclusion of the following conditions before assigning a myocardial infarction code.

📋 Clinical Indicators for Coders/CDI

Documentation must support the specific MI type and ECG classification to justify code assignment. The following indicators directly drive code selection and CC/MCC designation.

🦴 Anatomy & Pathophysiology

The coronary circulation consists of the left main coronary artery (LMCA), which bifurcates into the left anterior descending (LAD) and left circumflex (LCx) arteries, and the right coronary artery (RCA). In right-dominant anatomy (~85% of patients), the RCA supplies the posterior descending artery (PDA). The LAD supplies the anterior wall and apex; the LCx supplies the lateral wall; the RCA supplies the inferior wall and right ventricle.

Type 1 MI pathophysiology begins with vulnerable plaque rupture or erosion within a coronary artery. Exposure of subendothelial collagen triggers platelet aggregation and thrombin generation, forming an acute thrombus that partially or completely occludes the lumen. Complete occlusion typically produces STEMI; partial occlusion produces NSTEMI. Ischemia progresses from subendocardium outward (wavefront phenomenon), with irreversible necrosis beginning within 20–40 minutes of complete ischemia and completing within 4–6 hours. Reperfusion by PCI or thrombolytics within this window salvages at-risk myocardium.

Type 2 MI pathophysiology involves supply-demand mismatch without plaque rupture. Reduced oxygen supply (severe anemia, hypotension, respiratory failure, coronary spasm) or increased demand (sustained tachyarrhythmia, severe hypertension) exceeds myocardial oxygen delivery capacity in the setting of fixed or dynamic coronary stenoses. This mechanism accounts for an estimated 25–30% of all MI presentations and carries distinct management implications per the ACC’s summary of the 4th Universal Definition.

Infarction consequences include myocyte necrosis, ventricular remodeling, reduced ejection fraction, susceptibility to arrhythmia (VT/VF in first 24 hours), mechanical complications (papillary muscle rupture, free wall rupture, VSD), and longer-term heart failure if significant myocardium is lost.

💊 Medication Impact / Treatment

Pharmacologic management directly affects clinical trajectory and should be documented specifically to support CDI accuracy regarding complications (e.g., bleeding from anticoagulation) and acuity.

• Antiplatelet therapy: Aspirin (325 mg load, 81 mg maintenance) + P2Y12 inhibitor (ticagrelor, clopidogrel, prasugrel) — dual antiplatelet therapy (DAPT) is standard for ACS per 2025 ACC/AHA ACS Guidelines. Duration: 12 months post-stent for most patients.
• Anticoagulation: Unfractionated heparin (UFH), low-molecular-weight heparin (enoxaparin), bivalirudin, or fondaparinux during acute phase. Bleeding complications should be specifically documented and coded.
• Thrombolytics: Alteplase, tenecteplase — indicated for STEMI when PCI not available within 120 minutes. Administration of tPA warrants Z92.82 (status post administration of tPA in a different facility within last 24 hours) when applicable.
• Beta-blockers: Metoprolol, carvedilol — reduce mortality, prevent remodeling. Contraindicated in acute decompensated HF or cardiogenic shock.
• ACE inhibitors / ARBs: Lisinopril, ramipril — indicated for all MI patients with LVEF ≤40%, hypertension, or diabetes.
• Statins: High-intensity statin (atorvastatin 80 mg, rosuvastatin 40 mg) initiated in all MI patients regardless of baseline LDL.
• Nitrates: Sublingual or IV nitroglycerin for ongoing ischemic pain; withhold in right ventricular infarction (inferior STEMI with RV involvement).
• Mineralocorticoid receptor antagonists: Eplerenone/spironolactone post-MI with LVEF ≤40% and HF or diabetes.
• GLP-1 receptor agonists / SGLT2 inhibitors: Added post-MI in patients with diabetes for secondary prevention per updated guidelines.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO CDG members.

📘 ICD-10-CM Guidelines (FY2026)

The following guidelines apply per the FY2026 ICD-10-CM Official Guidelines for Coding and Reporting, Section I.C.9.e (Acute myocardial infarction).

Guideline I.C.9.e.1 — STEMI/NSTEMI Classification

Code I21.3 (STEMI of unspecified site) is the default when STEMI is documented without a specific wall location. If the provider documents “acute MI” without specifying STEMI or NSTEMI, code I21.9 (Acute myocardial infarction, unspecified). If NSTEMI evolves to STEMI, code the STEMI. If STEMI converts to NSTEMI due to thrombolytic therapy, still code the STEMI — the thrombolytic conversion does not change the original classification.

Guideline I.C.9.e.2 — Acute MI and Duration

Category I21 codes are used for MIs documented as acute or with a stated duration of 4 weeks (28 days) or less. After 28 days, the MI is considered healed and coded I25.2 (Old myocardial infarction), which carries no HCC weight and is used only for history/comorbidity purposes.

Guideline I.C.9.e.3 — Subsequent Acute MI (Category I22)

When a patient suffers a new MI within 28 days of an initial MI, use a code from category I22 (Subsequent ST elevation [STEMI] and non-ST elevation [NSTEMI] myocardial infarction) together with the category I21 code. Sequencing depends on the encounter circumstance — if the patient is seen primarily for the subsequent MI, I22 is sequenced as principal diagnosis. The I22 category applies only to subsequent Type 1 MI or unspecified MI. For a second occurrence of Type 2 MI within 28 days, report only I21.A1 (not I22). For Type 4 or Type 5 within 28 days, code only I21.A9.

Guideline I.C.9.e.4 — Type 2 MI Sequencing

Per ICD-10-CM guidance on Type 2 MI and AHA Coding Clinic direction, when a Type 2 MI occurs in the setting of another condition (e.g., sepsis, GI hemorrhage, severe anemia), sequencing follows the principal diagnosis rule. If sepsis is the principal diagnosis and Type 2 MI is a complication, the underlying condition is sequenced first, followed by I21.A1 with an additional code for the underlying cause. If the Type 2 MI is the reason for the encounter, I21.A1 may be the principal diagnosis, with an additional code for the precipitating condition.

Guideline I.C.9.e.5 — I21.B (Coronary Microvascular Dysfunction)

Code I21.B was added to capture MI with coronary microvascular dysfunction — part of the MINOCA (MI with non-obstructive coronary arteries) spectrum. This code applies when the provider documents MI attributable to microvascular disease, Takotsubo syndrome, or coronary spasm without obstructive plaque. This code carries MCC designation in the MS-DRG logic per CMS MS-DRG v43.0 Definitions.

🔢 ICD-10-CM Code Set (FY2026)

🔎 Indexing

Use the ICD-10-CM Alphabetic Index under the main term Infarct, infarction → myocardium, myocardial to locate codes. Key index pathways include:

• Infarct, infarction → myocardium → acute → ST elevation (STEMI) → anterior (anteroapical) (anterolateral) (anteroseptal) (Q wave) (wall) → involving left anterior descending coronary artery → I21.02
• Infarct → myocardium → acute → ST elevation → inferior (wall) → I21.11 (RCA) or I21.19 (other)
• Infarct → myocardium → acute → non-ST elevation (NSTEMI) → I21.4
• Infarct → myocardium → type 2 → I21.A1
• Infarct → myocardium → due to demand ischemia → I21.A1 (cross-references to Type 2)
• Infarct → myocardium → subsequent → I22.x
• Infarct → myocardium → old → I25.2
• Infarct → myocardium → healed or old → I25.2
• Infarction → myocardium → with coronary microvascular dysfunction → I21.B
• Injury, myocardial, non-ischemic → I5A (non-ischemic myocardial injury)

Tabular verification note: Always verify instructional notes in the I21 Tabular. The category carries “Use additional code, if applicable, for: exposure to tobacco smoke (Z77.22), tobacco dependence (F17.-), status post tPA (Z92.82).” The I21.A1 code includes a note to “code also the underlying cause” — failure to capture the precipitating condition for Type 2 MI represents an incomplete code set.

🏥 CPT (2026)

Procedure coding for myocardial infarction spans diagnostic (ECG, cardiac catheterization) and therapeutic (PCI, CABG) services. The following codes reflect AMA CPT 2026. Global period rules apply to all surgical procedures.

🧾 HCPCS (2026)

📚 AHA Coding Clinic (Recent Guidance)

The following summarizes key AHA Coding Clinic advisories relevant to myocardial infarction coding:

💰 HCC / Risk Adjustment (v28)

Under CMS-HCC Model v28, fully operative as of payment year 2026 (100% implementation), acute myocardial infarction maps to HCC 228 (Acute Myocardial Infarction). This replaces the prior V24 structure where AMI mapped to HCC 86.

Key v28 note: Under HCC v28, STEMI and NSTEMI are consolidated into a single HCC 228 (Acute Myocardial Infarction), whereas earlier discussions anticipated separate HCC 222/223 designations. As confirmed by the CMS-HCC v28 code list, HCC 228 captures all I21.x acute MI codes. The RAP coefficient of approximately 0.252 for a community, non-dual, aged beneficiary reflects meaningful reimbursement impact in Medicare Advantage. V28 is 100% operative for payment year 2026, replacing the prior phase-in approach.

✍️ CDI Query Templates

All queries below are compliant with ACDIS and AHIMA query guidelines — non-leading, multiple-choice format, presented as a request for clinical judgment, not a directive to change a diagnosis.

🧑‍⚕️ Treatments (Clinical)

Clinical management of MI is time-dependent and varies by MI type. Coders and CDI specialists must understand the treatment context to evaluate whether additional diagnoses (HF, shock, arrhythmia) are present and appropriately documented.

STEMI (Type 1)

• Primary PCI (pPCI): Goal door-to-balloon ≤90 minutes; preferred reperfusion strategy per 2025 ACC/AHA ACS Guidelines. Drug-eluting stent preferred over bare metal stent.
• Fibrinolysis: When pPCI not available within 120 minutes; tenecteplase (TNK) or alteplase (tPA); contraindicated with prior hemorrhagic stroke, active bleeding, severe HTN.
• Anticoagulation: Unfractionated heparin, bivalirudin, or enoxaparin during PCI.
• DAPT: Aspirin + ticagrelor (preferred) or clopidogrel for 12 months post-stent.
• Beta-blockers: Oral metoprolol within 24 hours if hemodynamically stable; avoid in cardiogenic shock or reactive airway disease.
• ACE inhibitors: All STEMI patients, especially with LVEF <40%.
• Statins: High-intensity statin started before discharge.

NSTEMI (Type 1)

• Risk stratification: TIMI or GRACE score; high-risk patients proceed to early invasive strategy (cath within 24 hours).
• Anticoagulation + antiplatelet: Same as STEMI; PCI performed electively within 24–72 hours based on risk score.
• Medical management: Nitrates, beta-blockers, oxygen if hypoxic (SpO₂ <90%); statins; ACE inhibitors.

Type 2 MI (Demand Ischemia)

• Treat the underlying cause: Sepsis → antibiotics + fluid resuscitation; tachyarrhythmia → rate control; hemorrhage → transfusion; severe anemia → transfusion/iron.
• Cardiac catheterization: Generally not indicated acutely unless Type 1 cannot be excluded; individualized decision-making.
• Antiplatelet/anticoagulation: Risk-benefit assessment — may exacerbate bleeding if hemorrhage is the precipitating cause.
• Beta-blockers: May be used for rate control in tachycardia-driven Type 2 MI.

Cardiac Surgery (CABG)

• Indicated for left main stenosis, multivessel disease with LV dysfunction, or failed PCI.
• Emergency CABG for ongoing ischemia refractory to medical therapy and PCI.
• Cardioplegic arrest, on-pump or off-pump techniques; LIMA-to-LAD graft preferred for long-term patency.
• ICU care post-operatively; ventilator management; potential complications (sternal wound infection, stroke, low-output syndrome) should be specifically documented.

MS-DRG Mapping (FY2026)

Per the FY2026 Final Rule MS-DRG Relative Weights, AMI inpatient cases (without surgical procedure) map to MDC 05 (Diseases and Disorders of the Circulatory System):

Important: All I21.x and I22.x codes carry MCC designation in the DRG severity logic per CMS MS-DRG v43.0 definitions. Therefore, when AMI is a secondary diagnosis, it can elevate a case from DRG without CC/MCC to with MCC — a substantial weight increase. When AMI is the principal diagnosis on a medical case, the distinction between MCC (e.g., cardiogenic shock, mechanical ventilation) and CC (e.g., heart failure without shock, stable arrhythmia) among secondary diagnoses drives DRG 280 vs. 281 vs. 282. Cardiac catheterization or PCI during the same inpatient stay will reclassify the case to the cardiac catheterization DRG family (222–227) or PCI DRG (246–251), which typically carry higher relative weights.

🎓 Patient Education / Summary

This section provides plain-language content useful for patient education materials, discharge instructions, and CDI conversations with clinical staff about documentation expectations.

What Is a Heart Attack?

A heart attack (myocardial infarction) happens when blood flow to part of the heart muscle is suddenly blocked, causing the heart muscle to begin dying from lack of oxygen. The longer the blockage lasts, the more damage occurs. Prompt treatment — calling 911, reaching a hospital, and restoring blood flow — limits long-term damage.

STEMI vs. NSTEMI — What’s the Difference?

In a STEMI, the artery is completely blocked. This is a medical emergency requiring immediate reopening of the artery (usually by cardiac catheterization and stenting) within 90 minutes of hospital arrival. In an NSTEMI, the artery is partially blocked. It still requires urgent treatment, usually catheterization within 24–72 hours, but the timeline is slightly less urgent than STEMI.

Type 2 MI — A Different Kind of Heart Attack

A Type 2 MI occurs not from a blocked artery from plaque rupture, but because the heart had to work harder than its blood supply could support — for example, because of a severe infection (sepsis), very low blood pressure, or dangerously fast heart rate. Treatment focuses on fixing the underlying problem. It is important for patients and care teams to understand this distinction because the treatment approach differs significantly from a traditional heart attack.

After a Heart Attack — Key Medications

• Aspirin — blood thinner to prevent clots; take daily
• P2Y12 inhibitor (ticagrelor, clopidogrel) — another blood thinner; do not stop without consulting your cardiologist
• Beta-blocker — slows the heart rate and reduces strain
• ACE inhibitor — protects the heart from further damage
• Statin — cholesterol medication to prevent future heart attacks

Warning Signs — When to Call 911

Call 911 immediately for: chest pain or pressure lasting more than a few minutes; pain spreading to arm, jaw, neck, or back; sudden shortness of breath; cold sweat; nausea or lightheadedness. Do not drive yourself to the hospital.

Documentation Note for Clinical Staff

Accurate documentation of MI type (STEMI location, NSTEMI, Type 2 MI vs. myocardial injury), duration, precipitating cause, and any complications (HF, arrhythmia, cardiogenic shock) is essential for proper coding, quality reporting, and Medicare Advantage risk adjustment. When in doubt, the CDI team will send a compliant query to clarify — please respond with your best clinical judgment based on the total clinical picture.

Sources: Fourth Universal Definition of Myocardial Infarction, Thygesen et al., Circulation 2018 | FY2026 ICD-10-CM Official Guidelines, CMS/CDC | CMS MS-DRG v43.0 Definitions Manual | FY2026 MS-DRG Relative Weights Table | CMS-HCC Model V28 Overview, RAAPID | ACC 4th Universal Definition of MI Summary | AHA Coding Clinic | AMA CPT 2026

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)